150 related articles for article (PubMed ID: 29571993)
1. Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials?
Hudson A; Chan C; Woolf D; McWilliam A; Hiley C; O'Connor J; Bayman N; Blackhall F; Faivre-Finn C
Lung Cancer; 2018 Apr; 118():139-147. PubMed ID: 29571993
[TBL] [Abstract][Full Text] [Related]
2. Neo-adjuvant chemotherapy followed by either continuous hyper-fractionated accelerated radiation therapy week-end less or conventional chemo-radiotherapy in locally advanced NSCLC-A randomised prospective single institute study.
Kumar R; Kumar HS; Paramanandhan M; Purohit R; Sharma N; Jakhar SL; Sharma S; Maharia S; Rai RK
J Cancer Res Ther; 2020; 16(4):860-866. PubMed ID: 32930131
[TBL] [Abstract][Full Text] [Related]
3. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.
Ahn JS; Ahn YC; Kim JH; Lee CG; Cho EK; Lee KC; Chen M; Kim DW; Kim HK; Min YJ; Kang JH; Choi JH; Kim SW; Zhu G; Wu YL; Kim SR; Lee KH; Song HS; Choi YL; Sun JM; Jung SH; Ahn MJ; Park K
J Clin Oncol; 2015 Aug; 33(24):2660-6. PubMed ID: 26150444
[TBL] [Abstract][Full Text] [Related]
4. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
5. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
Komaki R; Scott C; Lee JS; Urtasun RC; Byhardt RW; Emami B; Andras EJ; Asbell SO; Rotman M; Cox JD
Am J Clin Oncol; 1997 Oct; 20(5):435-40. PubMed ID: 9345325
[TBL] [Abstract][Full Text] [Related]
6. Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial.
Bi N; Liang J; Zhou Z; Chen D; Fu Z; Yang X; Feng Q; Hui Z; Xiao Z; Lv J; Wang X; Zhang T; Wang X; Deng L; Wang W; Wang J; Liu L; Hu C; Wang L
JAMA Netw Open; 2019 Dec; 2(12):e1918070. PubMed ID: 31851351
[TBL] [Abstract][Full Text] [Related]
7. The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial).
van Diessen J; De Ruysscher D; Sonke JJ; Damen E; Sikorska K; Reymen B; van Elmpt W; Westman G; Fredberg Persson G; Dieleman E; Bjorkestrand H; Faivre-Finn C; Belderbos J
Radiother Oncol; 2019 Feb; 131():166-173. PubMed ID: 30327236
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04.
Komaki R; Seiferheld W; Ettinger D; Lee JS; Movsas B; Sause W
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):548-57. PubMed ID: 12062596
[TBL] [Abstract][Full Text] [Related]
9. Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer Database.
Brower JV; Amini A; Chen S; Hullett CR; Kimple RJ; Wojcieszynski AP; Bassetti M; Witek ME; Yu M; Harari PM; Baschnagel AM
Ann Oncol; 2016 Oct; 27(10):1887-94. PubMed ID: 27502703
[TBL] [Abstract][Full Text] [Related]
10. Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer.
Conibear J;
Br J Cancer; 2020 Dec; 123(Suppl 1):10-17. PubMed ID: 33293671
[TBL] [Abstract][Full Text] [Related]
11. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.
Curran WJ; Paulus R; Langer CJ; Komaki R; Lee JS; Hauser S; Movsas B; Wasserman T; Rosenthal SA; Gore E; Machtay M; Sause W; Cox JD
J Natl Cancer Inst; 2011 Oct; 103(19):1452-60. PubMed ID: 21903745
[TBL] [Abstract][Full Text] [Related]
12. High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study.
Liu YE; Lin Q; Meng FJ; Chen XJ; Ren XC; Cao B; Wang N; Zong J; Peng Y; Ku YJ; Chen Y
Radiat Oncol; 2013 Aug; 8(1):198. PubMed ID: 23937855
[TBL] [Abstract][Full Text] [Related]
13. Accelerated, Dose escalated, Sequential Chemoradiotherapy in Non-small-cell lung cancer (ADSCaN): a protocol for a randomised phase II study.
Hatton MQF; Lawless CA; Faivre-Finn C; Landau D; Lester JF; Fenwick J; Simões R; McCartney E; Boyd KA; Haswell T; Shaw A; Paul J
BMJ Open; 2019 Jan; 9(1):e019903. PubMed ID: 30700475
[TBL] [Abstract][Full Text] [Related]
14. Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial.
Lin Q; Liu YE; Ren XC; Wang N; Chen XJ; Wang DY; Zong J; Peng Y; Guo ZJ; Hu J
Radiat Oncol; 2013 Aug; 8(1):201. PubMed ID: 23957889
[TBL] [Abstract][Full Text] [Related]
15. Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.
Mertsoylu H; Köse F; Sümbül AT; Sedef AM; Doğan Ö; Besen AA; Parlak C; Fındıkçıoğlu A; Muallaoğlu S; Sezer A; Sakallı H; Özyılkan Ö
Med Sci Monit; 2015 Mar; 21():661-6. PubMed ID: 25731741
[TBL] [Abstract][Full Text] [Related]
16. Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?
Hendriks LEL; Brouns -JWM; Amini M; Uyterlinde W; Wijsman R; Bussink J; Biesma B; Oei SB; Stigt JA; Bootsma GP; Belderbos JSA; De Ruysscher DKM; Van den Heuvel MM; Dingemans AC
Lung Cancer; 2016 Nov; 101():68-75. PubMed ID: 27794410
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress).
Kaira K; Mouri A; Kato S; Yoshimura K; Kagamu H; Kobayashi K
BMC Cancer; 2020 Oct; 20(1):961. PubMed ID: 33023530
[TBL] [Abstract][Full Text] [Related]
18. Definitive chemotherapy and radiotherapy in patients with stage II non-small cell lung cancer: A population-based outcomes study.
Sampath S; Hall M; Schultheiss TE
Lung Cancer; 2015 Oct; 90(1):61-4. PubMed ID: 26231092
[TBL] [Abstract][Full Text] [Related]
19. Continuous hyperfractionated accelerated radiotherapy - Escalated dose (CHART-ED): A phase I study.
Hatton MQ; Hill R; Fenwick JD; Morgan SA; Wilson PC; Atherton PJ; Dickson J; Murray KE; Paul J
Radiother Oncol; 2016 Mar; 118(3):471-7. PubMed ID: 26687902
[TBL] [Abstract][Full Text] [Related]
20. Dose escalation to 84 Gy with concurrent chemotherapy in stage III NSCLC appears excessively toxic: Results from a prematurely terminated randomized phase II trial.
Hallqvist A; Bergström S; Björkestrand H; Svärd AM; Ekman S; Lundin E; Holmberg E; Johansson M; Friesland S; Nyman J
Lung Cancer; 2018 Aug; 122():180-186. PubMed ID: 30032828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
